HR-positive breast cancer is a subtype of breast cancer characterised by the presence of hormone receptors on the surface of the cancer cells. This means that the growth of the cancer is driven by hormones, specifically estrogen and progesterone. Understanding this type of breast cancer is crucial for determining the most effective treatment strategies.

What does HR-positive breast cancer mean?

HR-positive breast cancer has cells that possess receptors for hormones like estrogen (ER-positive) and progesterone (PR-positive). These hormones can promote the growth of the cancer cells. This subtype is common, accounting for a significant proportion of breast cancer cases. The presence of these receptors influences treatment options and outcomes, making it a critical factor in breast cancer management.

How does HR-Positive breast cancer differ from other types?

1. Hormone Receptor Status: The defining characteristic of HR-positive breast cancer is its hormone receptor status. Unlike triple-negative breast cancer, which lacks hormone receptors, HR-positive cancer responds to hormone therapies designed to block these receptors.
2. Treatment Options: The presence of hormone receptors in HR-positive breast cancer allows for targeted treatments. One of them is Palbociclib, an anticancer medicine that works by inhibiting specific proteins involved in cell division. Hormone therapies, including selective estrogen receptor modulators (SERMs) and aromatase inhibitors, are also effective.
3. Prognosis: HR-positive breast cancer generally has a better prognosis compared to hormone receptor-negative subtypes. The availability of targeted treatments and the typically slower growth rate of HR-positive tumours contribute to this improved outlook.

What is the new treatment for HR-positive breast cancer?

1. Hormone Therapy: This is the cornerstone of treatment for HR-positive breast cancer. Hormone therapies work by blocking the effects of estrogen and progesterone, either by lowering hormone levels in the body or by preventing hormones from binding to their receptors on cancer cells.
2. Targeted Therapy: Palbace 125mg Capsule containing Palbociclib is a targeted therapy used in combination with hormone therapy for advanced HR-positive breast cancer. It inhibits cyclin-dependent kinases (CDKs), proteins that are involved in cell division, thereby slowing the growth of cancer cells.
3. Chemotherapy: While not always the first line of treatment, chemotherapy may be used in cases where the cancer is more aggressive or has spread beyond the breast and lymph nodes.
4. Surgery: Surgical options, such as lumpectomy or mastectomy, are common for removing the tumour. The choice of surgery depends on the size and location of the cancer and patient preference.
5. Radiation Therapy: Often used after surgery, radiation therapy targets any remaining cancer cells in the breast, chest wall, or lymph nodes. It reduces the risk of cancer recurrence.

What is the lifestyle of a breast cancer survivor?

1. Diet and Nutrition: Maintaining a balanced diet rich in fruits, vegetables, lean proteins, and whole grains can support overall health and recovery. Certain foods help manage side effects and improve treatment outcomes.
2. Exercise: Regular physical activity can reduce fatigue, improve mood, and enhance overall well-being. It's important to tailor exercise routines to individual capabilities and energy levels.
3. Mental Health Support: Coping with breast cancer can be emotionally challenging. Accessing mental health support, such as counselling or support groups, can provide emotional relief and improve quality of life.

What new research is being done on breast cancer?

Research in HR-positive breast cancer is ongoing, with numerous studies focused on improving treatment outcomes and reducing side effects. Innovations in targeted therapies and hormone treatments continue to emerge, offering new hope for patients.

1. CDK4/6 Inhibitors: Cancer medicines represent a significant advancement in the treatment of HR-positive breast cancer. By targeting specific pathways involved in cancer cell division, these medications offer an effective option for controlling advanced disease.
2. Combination Therapies: Researchers are exploring the benefits of combining different types of treatments, such as hormone therapy with targeted medicines, to enhance efficacy and overcome resistance.
3. Personalised Medicine: Advances in genetic testing and molecular profiling allow for more personalised treatment plans. By understanding the specific characteristics of a patient's cancer, doctors can tailor therapies to achieve the best possible outcomes.

Targeted and hormone treatments play a crucial role. Patients with HR-positive breast cancer have access to a range of options that can significantly improve their prognosis. Ongoing research continues to advance our knowledge and treatment strategies, offering hope and better outcomes for those affected by this common form of breast cancer.